What is the mechanism of action of reslizumab, and when is it indicated for the treatment of asthma?

Updated: Jan 07, 2019
  • Author: Michael J Morris, MD, FACP, FCCP; Chief Editor: Zab Mosenifar, MD, FACP, FCCP  more...
  • Print
Answer

Reslizumab is an IgG kappa monoclonal antibody that inhibits IL-5. It was approved by the FDA in March 2016 and is indicated for add-on maintenance treatment of patients with severe asthma aged 18 years and older with an eosinophilic phenotype. It is administered as an intravenous infusion every 4 weeks. Approval was based on three multicenter, international trials in patients with asthma who had elevated eosinophils. In two of these studies (n = 953), patients who received reslizumab had a significant reduction in the frequency of asthma exacerbations of up to 59% (study 1: rate ratio, 0.50 [95% confidence interval, 0.37-0.67]; study 2: rate ratio, 0.41 [95% confidence interval, 0.28-0.59]; both P <.0001) compared with those receiving placebo. [87]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!